2026 Marketing Small Molecule 
Drug Target Review
JULY 4, 2023
These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 3D rendering of Antibody Drug Conjugate Molecules.
The Pharma Data
MAY 2, 2023
Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. This step is crucial for Boehringer Ingelheim to rapidly advance new drug candidates from the company’s vast research pipeline to clinical trials and ultimately to market approval.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JANUARY 4, 2024
This is in part due to a complex manufacturing process, which is harder to control than those used for other modalities (such as small molecules and monoclonal antibodies). By this point, we have undertaken a thorough analysis of what the market will look like at the anticipated product launch, including potential reimbursement models.
Drug Discovery World
JANUARY 24, 2024
Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. MT: Your appointment comes as Fibrocor seeks to advance two drug candidates – exquisitely specific kinase inhibitor small molecules (FIB992 and FIB991) for rare indications into the clinic. PW: FIB992 is our lead compound.
Drug Discovery World
SEPTEMBER 6, 2022
Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. The challenge for the market then, according to Boissel, is how much can a payor afford to pay upfront? .
The Pharma Data
DECEMBER 12, 2020
AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. 1 The global rare disease market is forecasted to grow by a low double digit percentage in the future.
The Pharma Data
JANUARY 6, 2021
This new facility will offer large-scale cell culture manufacturing of bulk drug substance with 8 x 20,000L bioreactors (physical volume), with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand. “ The United States is the world’s biggest market for biopharmaceuticals.
Expert insights. Personalized for you.
145 
Let's personalize your content